Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases. With a state-of-the-art facility for biopharmaceutical product development and manufacturing and highly experienced pharmaceutical industry leadership, Scinai offers end-to-end boutique CDMO services in parallel to developing its own pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized VHH antibody (NanoAb) pipeline targeting diseases with large unmet medical needs. Company website: www.scinai.com
Company Details
- Employees
- 32
- Address
- Jerusalem Biopark, Hadassah Ein Kerem Campus,israel
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- biondvax.com
- Keywords
- BiondVax, Biotechnology, Recombinant Proteins, Clinical Trials, Nasdaq, Infectious diseases, Pharmaceutical, Pharmaceutical Manufacturing, GMP, GXP, Therapeutics, nanobodies, NanoAbs, antibodies, CDMO, Scinai, Immunotherapeutics.
- HQ
- Jerusalem, Jerusalem
Scinai Immunotherapeutics Ltd. Questions
Scinai Immunotherapeutics Ltd.'s website is biondvax.com
Scinai Immunotherapeutics Ltd.'s LinkedIn profile is https://il.linkedin.com/company/scinai
Scinai Immunotherapeutics Ltd. has
32 employees.
View email and phone details for 32
employees at Scinai Immunotherapeutics Ltd..
Scinai Immunotherapeutics Ltd.'s industry is
Biotechnology Research
Scinai Immunotherapeutics Ltd.'s top competitors are
Niagen Bioscience,
Anima Biotech,
Protalix Biotherapeutics,
Biolinerx,
Cytoreason,
Immunovative Therapies Ltd.,
Biond Biologics Ltd,
Gamida Cell Ltd.,
Biomx (Nyse: Phge),
Pluri.
Scinai Immunotherapeutics Ltd.'s categories are Biotechnology Research
